Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces
Post# of 421
(Total Views: 167)
Posted On: 07/28/2023 4:34:56 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Newly Granted Patent for DehydraTECH(TM)–Nicotine by United States Patent and Trademark Office
- Lexaria’s new patent includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in sublingual delivery formats like oral pouches
- The global oral nicotine pouch market was valued at $4.69 billion in 2022 and is expected to grow to $11.91 billion by 2029, driven by the growing ban on e-cigarettes worldwide
- The white pouch category is one of the fastest-growing, tobacco-free alternatives to smoking and vaping – growing at a CAGR of 13.4%
Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, has announced that the United States Patent and Trademark Office (“USPTO”) has granted a strategically important new patent in the oral nicotine sector for its patented DehydraTECH(TM) technology. The granting of the new patent further substantiates the superior DehydraTECH processing and sublingual compositions through exceptional scientific study results and recognition by the USPTO (https://nnw.fm/tRtGV ).
Lexaria’s new patent, US patent #11,700,875 Compositions and Methods For Sublingual Delivery of Nicotine, includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in sublingual delivery formats like oral pouches. DehydraTECH-nicotine has shown in multiple sets of animal testing that it can be delivered to the bloodstream up to 10-times to 20-times faster at up to 10-fold higher levels of nicotine into blood plasma from oral absorption than concentration-matched controls. The speed of onset has proven vital to nicotine users.
The oral nicotine pouch category interests Lexaria and the nicotine products industry, growing partly because of its reduced risk of health outcomes, as the US Food and Drug Administration has previously noted. The white pouch delivery method specifically avoids harmful lung outcomes experienced by smokers or vapers. It involves absorption primarily through the buccal and sublingual tissues of the mouth of purified nicotine that has been separated from the harmful substances found in most other formats.
The global oral nicotine pouch market was valued at $4.69 billion in 2022 and is growing at a CAGR of 13.4% (https://nnw.fm/S50ya ). By 2029, the market is expected to reach $11.91 billion – driven by multiple countries banning the sale of e-cigarettes, the devices used in vaping. Currently, 37 countries have banned these devices, representing a cumulative population of over 2.3 billion people (https://nnw.fm/rNvgS ). The initial purpose of vaping was to help wean people off cigarette use, but it has become controversial and is limited in certain countries, with many restrictions and bans worldwide.
The US-granted patent is also progressing as a patent application through other jurisdictions internationally. The US patent and international patent applications are partly supported by the superior pharmacokinetic blood plasma data from Lexaria in its animal studies conducted from 2017 through 2021. This new patent builds nicely upon the company’s growing patent portfolio in the oral nicotine delivery sector, including the white pouch category for sublingual and buccal tissue delivery. The patents are built on a foundation of nicotine-specific patent filings dating back to 2019 and DehydraTECH patents dating back to 2016.
Lexaria’s DehydraTECH-nicotine has patents granted for oral nicotine delivery in the US, Canada, Australia, and is pending in numerous other countries. The white pouch category is one of the fastest growing, tobacco-free alternatives to smoking and vaping – emitting no smoke, odors, or vapors that can affect nearby persons and are a superior nicotine delivery method. Lexaria demonstrates this through its granted patents, subsequent studies, and future endeavors for sublingual and buccal delivery with DehydraTECH.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria’s new patent includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in sublingual delivery formats like oral pouches
- The global oral nicotine pouch market was valued at $4.69 billion in 2022 and is expected to grow to $11.91 billion by 2029, driven by the growing ban on e-cigarettes worldwide
- The white pouch category is one of the fastest-growing, tobacco-free alternatives to smoking and vaping – growing at a CAGR of 13.4%
Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, has announced that the United States Patent and Trademark Office (“USPTO”) has granted a strategically important new patent in the oral nicotine sector for its patented DehydraTECH(TM) technology. The granting of the new patent further substantiates the superior DehydraTECH processing and sublingual compositions through exceptional scientific study results and recognition by the USPTO (https://nnw.fm/tRtGV ).
Lexaria’s new patent, US patent #11,700,875 Compositions and Methods For Sublingual Delivery of Nicotine, includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in sublingual delivery formats like oral pouches. DehydraTECH-nicotine has shown in multiple sets of animal testing that it can be delivered to the bloodstream up to 10-times to 20-times faster at up to 10-fold higher levels of nicotine into blood plasma from oral absorption than concentration-matched controls. The speed of onset has proven vital to nicotine users.
The oral nicotine pouch category interests Lexaria and the nicotine products industry, growing partly because of its reduced risk of health outcomes, as the US Food and Drug Administration has previously noted. The white pouch delivery method specifically avoids harmful lung outcomes experienced by smokers or vapers. It involves absorption primarily through the buccal and sublingual tissues of the mouth of purified nicotine that has been separated from the harmful substances found in most other formats.
The global oral nicotine pouch market was valued at $4.69 billion in 2022 and is growing at a CAGR of 13.4% (https://nnw.fm/S50ya ). By 2029, the market is expected to reach $11.91 billion – driven by multiple countries banning the sale of e-cigarettes, the devices used in vaping. Currently, 37 countries have banned these devices, representing a cumulative population of over 2.3 billion people (https://nnw.fm/rNvgS ). The initial purpose of vaping was to help wean people off cigarette use, but it has become controversial and is limited in certain countries, with many restrictions and bans worldwide.
The US-granted patent is also progressing as a patent application through other jurisdictions internationally. The US patent and international patent applications are partly supported by the superior pharmacokinetic blood plasma data from Lexaria in its animal studies conducted from 2017 through 2021. This new patent builds nicely upon the company’s growing patent portfolio in the oral nicotine delivery sector, including the white pouch category for sublingual and buccal tissue delivery. The patents are built on a foundation of nicotine-specific patent filings dating back to 2019 and DehydraTECH patents dating back to 2016.
Lexaria’s DehydraTECH-nicotine has patents granted for oral nicotine delivery in the US, Canada, Australia, and is pending in numerous other countries. The white pouch category is one of the fastest growing, tobacco-free alternatives to smoking and vaping – emitting no smoke, odors, or vapors that can affect nearby persons and are a superior nicotine delivery method. Lexaria demonstrates this through its granted patents, subsequent studies, and future endeavors for sublingual and buccal delivery with DehydraTECH.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)